U.S. FDA Accepts Astellas ' New Drug Application for Fezolinetant

TOKYO, Aug. 18, 2022. Astellas Pharma Inc. ( " Astellas " ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ' s New Drug Application (NDA) for fezolinetant, an investigational oral, nonhormonal compound seeking...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials